The Omicron epidemic is spreading globally, and various localities are studying countermeasures. Good news came from the latest research results published in “Needle Needle”. After vaccination, the level of antibodies in the third needle was significantly increased, and the safety was good.
Studies have shown that 8 months after the second dose of Kexing vaccination, the antibody level of the third dose of vaccine increased significantly, and showed good safety.
A few days ago, the Hebei Provincial Center for Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, the Key Laboratory of Public Health Safety of Fudan University School of Public Health, Kexing Holding Biotechnology Co., Ltd. (SINOVAC Kexing), etc. The journal “Needle-Infectious Diseases” published the immunity persistence of two doses of SINOVAC Kexing’s new coronavirus inactivated vaccine Kellyf for healthy adults, and the immunogenicity and safety after the third dose was double-blind, randomized, and placebo Compare the results of Phase II clinical research.
Experts believe that this research is very important for epidemic prevention and control. AP pictures
Expert reviews published in the same period of “Needle” believe that this research is very important to the prevention and control of the epidemic, and it brings hope that people who have been vaccinated or will be vaccinated with the new crown inactivated vaccine around the world will be protected.
The study showed that although the antibody level will decrease 6 months after two doses of Kellyford, due to the development of immune memory, the antibody level will increase significantly when the third dose is given 8 months after the second dose, and shows Good security.
The study used SINOVAC Kexing’s new coronavirus inactivated vaccine Kellyford.
The study consisted of two independent clinical trials, namely the Phase II clinical trial of Kellyford in healthy adults aged 18-59 years in Jiangsu Province and the Phase II clinical trial of Kellyford in healthy elderly people over 60 years in Hebei Province. Clinical Trials.
The study consisted of 2 independent clinical trials.Profile picture
In the experiment of healthy people aged 18-59 years, subjects were divided into two different vaccination groups: the first group was vaccination group on day 0 and day 14, and the second group was vaccination group on day 0 and day 28 Vaccination group. Half of the subjects in each group received the third dose 2 months after the second dose, and the other half received the third dose 8 months after the second dose. The results showed that the neutralizing antibody titer (GMT) induced after the completion of two doses of Kellyford significantly decreased to 3.9 in the first group and 6.8 in the second group after 6 months. After the completion of the two doses, the GMT levels on the 14th and 28th days after the third dose of vaccination at an interval of 8 months can increase rapidly to 137.9 in the first group and 143.1 in the second group, respectively.
In the trial of healthy people aged 60 and over, subjects used the 0,28 vaccination program, and the third dose of vaccine was given 8 months after the completion of the second dose. The results showed that the neutralizing antibody titers of healthy people aged 60 years and older decreased significantly 6 months after receiving two doses of Kellyford. Inoculation of the third dose 8 months after the second dose, the neutralizing antibody titer increased significantly, and the GMT value increased from 42.9 at 28 days after the second dose to 158.5 at 28 days after the third dose.
All subjects in the clinical studies of the two age groups had an antibody positive rate as high as 98%-100% after the third dose at an interval of 8 months between the second dose. The adverse reactions reported within 28 days after the third dose of vaccine were all milder grade 1 or 2, well tolerated, and no difference compared with the previous two doses, showing good safety.
“Needles” published expert reviews at the same time.
In view of the important public health significance of this research, “Needle” also published a symposium jointly signed by Professor Julio Croda from the Federal University of Mato Grosso, Brazil, and Professor Otavio Ranzani, an epidemiologist at the International Health Institute in Barcelona, Spain.
The Omicron epidemic has spread globally. AP pictures
Experts believe that the study provides timely scientific basis for the need to vaccinate, when to vaccinate, and who needs to be immunized. This is very important for preventing the onset of new coronary pneumonia and the prevention and control of the epidemic.
The review pointed out that, so far, Kellyford has become the most widely used vaccine in the world. The high titers of neutralizing antibodies induced by the third dose of vaccine in adults of all ages indicate that Kellyford can produce good immune memory. After completing two doses of Kellyford, the third dose is given 8 months later. The neutralizing antibody titer of the new coronavirus can be increased to 3 to 5 times after the second dose of vaccination, while showing good safety.
Experts say this brings hope to people who have been or will be vaccinated with the new crown inactivated vaccine around the world will be protected. Further research should systematically evaluate and simulate when to give booster doses. In addition, in the context of the frequent occurrence of new crown mutations, the effectiveness of booster injections and changes in immunity should be further evaluated, which can better provide scientific evidence for the formulation of vaccination strategies.
.
